CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- 4 Open-market buy CEO and CFO bought 2,000 shares at $10.55 ($21,100)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $9.20 ($9,200)
- 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $9.49 ($2,373)
- 10-Q Report Quarterly Report
- 4 Open-market buy CEO and CFO bought 1,000 shares at $11.69 ($11,690)
- NT 10-Q Other NT 10-Q
- 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $11.22 ($2,805)
- 4 Open-market buy CEO and CFO bought 7,000 shares at $11.10 ($77,700)
- 4 Open-market buy CEO and CFO bought 2,000 shares at $11.12 ($22,240)
- 8-K Event Other events
- 4 Open-market buy VP Clinical Reg Affairs bought 1,000 shares at $11.87 ($11,870)
- 4 Open-market buy CEO and CFO bought 5,000 shares at $12.42 ($62,100)
- 10-K Report Annual Report
- 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $12.71 ($3,178)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $12.12 ($12,120)
- 8-K Event Other events
- 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $15.40 ($3,849)
- 4 Open-market buy CEO and CFO bought 600 shares at $16.53 ($9,918)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $18.68 ($18,680)
- 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $20.84 ($5,210)
Page 6 of 14 · 279 filings